SCHEMBL1832147

SCHEMBL1832147

NC(N)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445907 1.00
Hydrochloric Acid SCHEMBL2950615 0.96
SCHEMBL3668939 0.84
SCHEMBL4383615 0.84
SCHEMBL9115345 0.83
SCHEMBL3667003 0.81 EPHX1 (0.48)
SCHEMBL18402782 0.81 EPHX1 (0.48)
SCHEMBL80338 0.81
SCHEMBL10910429 0.81 EPHX1 (0.48)
SCHEMBL20211173 0.78 ALDH1A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091554-A1 NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS ICAGEN, LLC (US) 2023-05-25 WO disclosed
EP-3002284-B1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY HOFFMANN LA ROCHE (CH) 2019-05-22 EP disclosed
EP-2906549-B1 N-(2-(CYCLIC AMINE)ETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS MINDIMMUNE THERAPEUTICS INC (US) 2019-04-17 EP disclosed
US-8877741-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 US disclosed
US-20140213568-A1 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-31 US disclosed
EP-2318377-B1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH INC (US) 2013-08-21 EP disclosed
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2012-06-28 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
EP-2318377-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Genentech, Inc. (US) 2011-05-11 EP disclosed
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-03-18 US disclosed
WO-2010014939-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-02-04 WO disclosed
EP-1453801-B1 SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1515973-A1 PORPHYRIN-POLYAMINE CONJUGATES FOR CANCER THERAPY Cellgate Inc. (US) 2005-03-23 EP disclosed
WO-2004106285-A1 BENZAMIDE NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-09 WO disclosed
WO-2004002991-A1 PORPHYRIN-POLYAMINE CONJUGATES FOR CANCER THERAPY CELLGATE, INC. (US) 2004-01-08 WO disclosed
US-6107309-A BLOOD DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2000-08-22 US disclosed
EP-0171342-B1 SUBSTITUTED 2-(1-AMINO-AKYLIDENYL)1,3-INDANE DIONES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE CORTIAL S.A. (FR) 1987-10-07 EP disclosed
EP-0171342-A1 Substituted 2-(1-amino-akylidenyl)1,3-indane diones, process for their preparation and their therapeutical use CORTIAL S.A. (FR) 1986-02-12 EP disclosed